Defining novel Riplet-activated antiviral innate immune signaling pathways
定义新型 Riplet 激活的抗病毒先天免疫信号通路
基本信息
- 批准号:9310220
- 负责人:
- 金额:$ 19.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-08 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAntiviral AgentsAntiviral ResponseAntiviral TherapyAutoimmune DiseasesBindingBiochemicalBiological AssayCell LineCellsCleaved cellComplexDataDefectDengue VirusDevelopmentDiseaseGeneticGenome engineeringGoalsGrowthHepatitis CHost DefenseImmuneImmune EvasionImmune responseImmune signalingInfectionInfluenzaInnate Immune ResponseInnate Immune SystemInterferonsKnowledgeLeadLengthLinkLiverMapsMediatingMembraneMolecularMorbidity - disease rateMutationNatural ImmunityOutcomePathway interactionsPattern recognition receptorPeptide HydrolasesPreventionProcessProductionProteinsProteomicsPublic HealthRNARNA Virus InfectionsRNA VirusesRecruitment ActivityRegulationRoleSendai virusSignal PathwaySignal TransductionSignaling ProteinSiteTestingTherapeuticUbiquitinUbiquitinationVaccinesViralVirusVirus DiseasesVirus ReplicationWorkarmbasecomparativedesigngenetic approachhepatoma cellimmunoregulationimprovedinnovationmortalitymutantnovelpathogenprogramspublic health relevanceubiquitin-protein ligaseviral RNA
项目摘要
DESCRIPTION (provided by applicant): The interferon antiviral defense program is activated by the host innate immune system upon sensing RNA virus infection. However, many RNA viruses have evolved mechanisms to subvert this defense program. The underlying host-viral interactions that dictate the outcome of viral infection, including the molecular mechanisms that regulate antiviral innate immune signaling to drive an effective immune response to virus infection, are not fully understood. An understanding of these processes is required to define the critical components that drive the first line of host defense to RNA virus infection. The hepatitis
C virus (HCV) NS3/4A protease cleaves the host antiviral signaling proteins Riplet and MAVS to block this antiviral signaling. Preliminary studies have identified a mutation in NS3/4A that inhibits Riplet cleavage while maintaining MAVS cleavage. Our studies using this mutant HCV have found that the E3 ubiquitin ligase Riplet regulates a signaling pathway independent of the known pattern recognition receptor and antiviral protein RIG-I that is essential for innate immunity to HCV. Therefore, the goal of this proposal is to define this Riplet-dependent, RIG-I independent antiviral signaling pathway. Based on our preliminary data, the central hypothesis of this proposal is that Riplet ubiquitinate a protein that drives a RIG-I independent antiviral signaling pathway that is regulated during HCV infection to control the antiviral response and outcome of infection. Guided by our preliminary data, this hypothesis will be tested by pursuing the following two specific aims: 1) Define the RIG-I independent innate immune signaling pathway regulated by Riplet; 2) Identify the targets of Riplet ubiquitination during HCV infection.
In Aim 1, the molecular mechanisms by which this RIG-I independent signaling pathway regulated by NS3/4A contributes to innate immune signaling and the antiviral response will be defined. In Aim 2, the specific ubiquitinated target(s) of Riplet will be identified and validated.
Taken together, the work proposed in this application will be significant because it will define a new antiviral innate immune signaling pathway that will have implications for the treatment and prevention of RNA virus infection and interferon-mediated autoimmune disease. The proposed work is innovative because it is the first to uncouple distinct innate immune regulatory mechanisms within the HCV NS3/4A protein that will be used to fully define the roles of Riplet and MAVS in the antiviral response and to uncover a new Riplet-regulated antiviral signaling pathway. Ultimately, an increased understanding of the regulation of innate immune pathways will improve our knowledge of the mechanistic causes of dysregulated interferon production that can lead to autoimmune disease, and it will define the mechanisms of immune protection for RNA virus infection that will have implications for therapeutic and vaccine strategies to limit RNA
virus infection.
描述(由申请人提供):干扰素抗病毒防御程序在感知RNA病毒感染时被宿主先天免疫系统激活。然而,许多RNA病毒已经进化出破坏这种防御程序的机制。决定病毒感染结果的潜在宿主-病毒相互作用,包括调节抗病毒先天免疫信号传导以驱动对病毒感染的有效免疫应答的分子机制,尚未完全理解。理解这些过程是必要的,以确定驱动宿主防御RNA病毒感染的第一道防线的关键组件。肝炎
丙型肝炎病毒(HCV)NS 3/4A蛋白酶切割宿主抗病毒信号蛋白Riplet和MAVS以阻断这种抗病毒信号传导。初步研究已经鉴定了NS 3/4A中抑制Riplet切割同时维持MAVS切割的突变。我们使用这种突变型HCV的研究发现,E3泛素连接酶Riplet调节的信号通路独立于已知的模式识别受体和抗病毒蛋白RIG-I,这是先天免疫HCV所必需的。因此,本提案的目标是定义这种Riplet依赖性、RIG-I独立性的抗病毒信号通路。基于我们的初步数据,该提议的中心假设是Riplet泛素化一种蛋白,该蛋白驱动在HCV感染期间受调节的RIG-I独立的抗病毒信号传导途径,以控制抗病毒应答和感染的结果。在我们的初步数据的指导下,这一假设将通过追求以下两个具体目标来检验:1)确定由Riplet调节的RIG-I独立的先天免疫信号传导途径; 2)确定HCV感染期间Riplet泛素化的靶点。
在目标1中,将定义由NS 3/4A调节的这种RIG-I独立信号传导途径有助于先天免疫信号传导和抗病毒应答的分子机制。在目标2中,将鉴定和验证Riplet的特异性泛素化靶标。
总之,本申请中提出的工作将是重要的,因为它将定义一种新的抗病毒先天免疫信号传导途径,其将对RNA病毒感染和干扰素介导的自身免疫性疾病的治疗和预防产生影响。这项工作具有创新性,因为它是第一个将HCV NS 3/4A蛋白中不同的先天免疫调节机制解偶联的工作,该机制将用于充分定义Riplet和MAVS在抗病毒反应中的作用,并揭示一种新的Riplet调节的抗病毒信号通路。最终,对先天免疫途径调节的更多理解将提高我们对干扰素产生失调的机制原因的认识,干扰素产生失调可导致自身免疫性疾病,并且它将确定RNA病毒感染的免疫保护机制,这将对限制RNA病毒感染的治疗和疫苗策略产生影响。
病毒感染。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
NS3-NS4A 靶向的非典型抗病毒信号通路可抑制丙型肝炎病毒感染。
- DOI:10.1128/jvi.00725-19
- 发表时间:2019
- 期刊:
- 影响因子:5.4
- 作者:Vazquez,Christine;Tan,ChinYee;Horner,StacyM
- 通讯作者:Horner,StacyM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stacy Michelle Horner其他文献
Stacy Michelle Horner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stacy Michelle Horner', 18)}}的其他基金
Regulation of RIG-I signaling and viral immune evasion by ufmylation
通过 ufmylation 调节 RIG-I 信号传导和病毒免疫逃避
- 批准号:
10620805 - 财政年份:2021
- 资助金额:
$ 19.88万 - 项目类别:
Regulation of RIG-I signaling and viral immune evasion by ufmylation
通过 ufmylation 调节 RIG-I 信号传导和病毒免疫逃避
- 批准号:
10414114 - 财政年份:2021
- 资助金额:
$ 19.88万 - 项目类别:
Regulation of RIG-I signaling and viral immune evasion by ufmylation
通过 ufmylation 调节 RIG-I 信号传导和病毒免疫逃避
- 批准号:
10295558 - 财政年份:2021
- 资助金额:
$ 19.88万 - 项目类别:
Defining the role of the RNA modification N6-methyladenosine in the hepatitis C virus lifecycle
定义 RNA 修饰 N6-甲基腺苷在丙型肝炎病毒生命周期中的作用
- 批准号:
9157887 - 财政年份:2016
- 资助金额:
$ 19.88万 - 项目类别:
Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection
定义 RNA 修饰 N6-甲基腺苷在黄病毒科病毒感染过程中的作用
- 批准号:
10444757 - 财政年份:2016
- 资助金额:
$ 19.88万 - 项目类别:
Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection
定义 RNA 修饰 N6-甲基腺苷在黄病毒科病毒感染过程中的作用
- 批准号:
10557139 - 财政年份:2016
- 资助金额:
$ 19.88万 - 项目类别:
Defining the role of the RNA modification N6-methyladenosine in the hepatitis C virus lifecycle
定义 RNA 修饰 N6-甲基腺苷在丙型肝炎病毒生命周期中的作用
- 批准号:
9283320 - 财政年份:2016
- 资助金额:
$ 19.88万 - 项目类别:
Defining novel Riplet-activated antiviral innate immune signaling pathways
定义新型 Riplet 激活的抗病毒先天免疫信号通路
- 批准号:
9090371 - 财政年份:2016
- 资助金额:
$ 19.88万 - 项目类别:
Zika virus infection of neural stem cells to model pathogen-induced microcephaly
寨卡病毒感染神经干细胞来模拟病原体诱导的小头畸形
- 批准号:
9266693 - 财政年份:2016
- 资助金额:
$ 19.88万 - 项目类别:
Innate immune regulation during hepatitis C virus infection
丙型肝炎病毒感染期间的先天免疫调节
- 批准号:
8352240 - 财政年份:2013
- 资助金额:
$ 19.88万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 19.88万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 19.88万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 19.88万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 19.88万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 19.88万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 19.88万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 19.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 19.88万 - 项目类别: